Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy. Treatment with an agent that inhibits leukocyte recruitment has therapeutic and preventative effects in blocking recurrent seizures and epilepsy.
1. A method of inhibiting recurrent seizures in an individual mammal subject to recurrent seizures, said method comprising:
administering to said individual mammal an effective amount of an antagonist of P-selectin selected from the group consisting of polypeptides and ligand-mimetic competitive antagonists, to inhibit the recurrence of seizures.
2. The method according to claim 1 , wherein said antagonist of P-selectin is an antibody that specifically binds PSGL-1 (P-selectin glycoprotein ligand-1).
3. The method according to claim 1 , wherein said antagonist is an antibody that specifically binds to P-selectin.
4. The method according to claim 1 , wherein said antagonist is YSPSL or rPSOL-Ig.
5. The method according to claim 1 , wherein said mammal is a human.
6. The method according to claim 5 , wherein said human has epilepsy.
7. A method of inhibiting recurrent seizures in an individual mammal, said method comprising:
administering to said individual mammal an effective amount of an antibody that specifically binds to p-selectin or PSGL-1, to inhibit the recurrence of seizures.
8. A method of preventing seizures in an individual mammal that has epilepsy, said method comprising:
administering to said individual mammal an effective amount of an antibody specific for p-selectin or PSGL-1 to inhibit the recurrence of seizures.